- Global Pharma News & Resources

Coave Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference

Paris, France, September 20, 2022 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, today announced that CEO Rodolphe Clerval will present a company overview at Chardan’s 6th Annual Genetic Medicines Conference at 8:30 am ET on October 3, 2022.

The presentation will highlight how Coave is developing next generation gene therapy products based on its proprietary AAV-Ligand Conjugate (‘ALIGATER’) platform to transform gene therapy for neurodegenerative and eye diseases. Coave’s ligand conjugated AAV capsids (coAAVs) derived from the ALIGATER platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies.

Chardan’s 6th Annual Genetic Medicines Conference is taking place October 3-4, 2022, in New York City and Rodolphe Clerval will be in attendance for the duration of the conference and available for one-to-one meetings. Use this link to find further information on the conference.

Editor Details

Related Links

Last Updated: 20-Sep-2022